Senate Special Committee on Aging Examines Drug Pricing

FOR IMMEDIATE RELEASE
March 17, 2016
Contact: Ben Jenkins
Email: [email protected]

Senate Special Committee on Aging Examines Drug Pricing

Ahead of this morning's Senate Special Committee on Aging hearing on drug pricing, John Rother, executive director of the Campaign for Sustainable Rx Pricing issued the following statement:

"Today's hearing shows that fighting high prescription drug prices is truly a bipartisan battle. Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It's unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice."

And, the problem of rising prescription drug prices is even more widespread than just Turing Pharmaceuticals or a few bad actors. Learn more about the startling pace of across-the-board price increases here in our fact sheet.

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.